Core Viewpoint - Fudan Zhangjiang has reported significant advancements in its R&D investments and clinical trials, particularly in the fields of antibody-drug conjugates (ADC) and photodynamic therapy drugs, indicating a strong potential for future growth and product diversification [1][2] Group 1: R&D Investments - The company invested approximately 358 million RMB in R&D during the reporting period, with a steady increase in the proportion of R&D spending relative to revenue [1] - R&D funding is primarily directed towards ADC and photodynamic drug development, with multiple pipelines achieving key progress [1] Group 2: ADC Developments - The Phase III clinical trial for the FDA018 ADC targeting triple-negative breast cancer has exceeded its enrollment target, with over 350 participants, and data collection is currently underway [1] - The Phase II clinical study for the FDA022 ADC, aimed at HER2 low-expressing breast cancer, has completed patient enrollment and successfully held a communication meeting with regulatory authorities [1] Group 3: Photodynamic Therapy Developments - The application for marketing authorization of the oral solution of aminolevulinic acid for intraoperative visualization in high-grade glioma has been accepted, which could enhance the company's product portfolio and core competitiveness in the photodynamic therapy sector [1] Group 4: Industrialization Support - Fudan Zhangjiang's wholly-owned subsidiary, Taizhou Fudan Zhangjiang, is providing support for the industrialization of its ADC projects, including technology transfer and production process validation [2] - The commercialization of related products is expected to create new growth points for the company, contributing to its long-term high-quality development [2]

Core Viewpoint - The company, Immune-Onc Therapeutics, is set to present the latest efficacy and safety results of its investigational B7H3 antibody-drug conjugate, DB-1311/BNT324, for treating previously treated metastatic castration-resistant prostate cancer (mCRPC) patients at the 2026 ASCO GU Cancer Symposium [1]. Group 1: Study Overview - The 1/2 phase study (NCT05914116) involves a dose-optimization cohort where mCRPC patients previously treated received DB-1311/BNT324 at doses of 6 mg/kg or 9 mg/kg every three weeks [1]. - In the dose-expansion cohort, patients who had received Lu 177 treatment and those who had not received taxane therapy were administered 6 mg/kg every three weeks until disease progression or intolerable toxicity occurred [1]. Group 2: Patient Demographics and Treatment Outcomes - As of September 5, 2025, 104 mCRPC patients had received DB-1311/BNT324 treatment, with a median follow-up of 9.2 months; 50% of patients remained on treatment [2]. - The median age of patients was 70 years, with a majority being white (53%), followed by Asian (31%) and Black (13%); the median number of prior treatments was 4 [2]. - Among 58 patients eligible for tumor response assessment, the unconfirmed objective response rate was 41.4%, and the confirmed objective response rate was 34.5%, with a disease control rate of 87.9% [2]. Group 3: Progression-Free Survival and Overall Survival - In 82 patients evaluable for radiographic progression-free survival (rPFS), the median rPFS was 11.3 months, with 6-month and 9-month rPFS rates of 72.0% and 63.0%, respectively [2]. - Overall survival (OS) data was not yet mature, but the 6-month and 9-month OS rates were reported at 91.7% and 88.2% [3]. Group 4: Safety Profile - The safety profile was consistent with previous reports, with the most common adverse events being nausea and hematological events, primarily grade 1-2 [3]. - Among the 104 patients, 34 (33%) had previously received Lu 177 treatment, with similar outcomes observed between those who had and had not received Lu 177, although the PSA duration of response was shorter in the former group [3].

中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團全 資附屬公司禮新醫藥科技（上海）有限公司（「禮新醫藥」）自主研發的國家1類創新藥維特柯妥拜單抗（研 發代號：LM-302）「CLDN18.2 ADC」正在開展用於治療三線及以上CLDN18.2陽性的局部晚期或轉移 性胃及胃食管交界部腺癌的III期註冊臨床試驗(LM302-03-101)，已順利完成患者入組。其中，LM- 302是全球首款完成註冊III期臨床試驗入組的CLDN18.2 ADC藥物。 LM-302是一款靶向CLDN18.2的抗體偶聯藥物(ADC)，通過與CLDN18.2陽性腫瘤細胞特異性結合， 並經內吞作用進入細胞後釋放小分子毒素，從而實現對腫瘤細胞的精準殺傷。作為潛在同類首創 (FIC)藥物，LM-302在胃癌、胰腺癌及膽道癌等多個消化道腫瘤中展現出良好的臨床開發潛力，並有 望為CLDN18.2低表達和PD-L1低表達患者提供新的治療選擇。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生 ...

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. announced that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the fourth indication of its core product, TROP2 ADC, sac-TMT, for the treatment of 2L+ HR+/HER2- breast cancer [2][6]. Drug Basic Information - The approval is based on positive results from the OptiTROP-Breast02 Phase III clinical study, which was presented at the 2025 European Society for Medical Oncology (ESMO) Congress [2][3]. - The new indication is for adult patients with unresectable or metastatic HR+/HER2- breast cancer who have previously received endocrine therapy and at least one line of chemotherapy [2][3]. Clinical Study Results - The OptiTROP-Breast02 study evaluated the efficacy and safety of sac-TMT compared to investigator's choice of chemotherapy in patients with HR+/HER2- breast cancer [3]. - Among enrolled patients, 95.7% had visceral metastases, and 75.9% had liver metastases [3]. - The study showed a significant improvement in progression-free survival (PFS) for the sac-TMT group compared to the chemotherapy group (8.3 months vs. 4.1 months; hazard ratio (HR): 0.35; 95% confidence interval (CI): 0.26-0.48; p<0.0001) [3]. - The overall survival (OS) benefit trend and objective response rate (ORR) were also significantly higher in the sac-TMT group (41.5% vs. 24.1%) [3]. Product Overview - Sac-TMT is a novel TROP2 ADC developed by Kelun Botai, targeting various advanced solid tumors, including non-small cell lung cancer (NSCLC), breast cancer (BC), gastric cancer (GC), and gynecological tumors [5]. - The drug utilizes a new linker and has a drug-antibody ratio (DAR) of 7.4, delivering a topoisomerase I inhibitor as an effective payload [5]. - Sac-TMT has received six breakthrough therapy designations (BTD) from the NMPA [6]. Ongoing Research - Currently, sac-TMT is involved in nine registration clinical studies in China, with Merck conducting 16 ongoing global Phase III clinical studies for various cancer types [7].

相关事件 格隆汇2月6日丨科伦博泰生物-B(06990.HK)发布公告，近日，公司靶向人滋养细胞表面抗原2(TROP2) 的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱®)的一项新增适应症 上市申请已获中国国家药品监督管理局(NMPA)批准，用于治疗既往接受过内分泌治疗且在晚期疾病阶 段接受过至少一线化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子受体2阴性 (HER2-)(免疫组织化学(IHC)0、IHC1+或IHC2+/原位杂交(ISH)-)乳腺癌(BC)成人患者。此次获批的至少 经一线化疗治疗HR+/HER2-BC是芦康沙妥珠单抗(sac-TMT)在中国上市的第四项适应症。 科伦博泰生物-B(06990.HK)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)获国家药监局批准第四项 适应症上市，用于治疗2L+HR+/HER2-乳腺癌 科伦博泰生物-B(06990.HK)与华润科伦续签2026年研发相 关物资框架协议 本次获批基于OptiTROP-Breast02 3期临床研究的积极结果，该研究已在2025年欧洲肿瘤内科学会 (E ...

目前，芦康沙妥珠单抗(sac-TMT)联合╱不联合帕博利珠单抗(可瑞达2)用于治疗既往接受过内分泌治疗 但未接受过化疗的HR+/HER2-BC患者的全球(NCT06312176)和中国(NCT07071337)的3期临床研究均已 启动。 本次获批基于OptiTROP-Breast023期临床研究的积极结果，该研究已在2025年欧洲肿瘤内科学会 (ESMO)大会入选最新突破性摘要(LBA)并以口头报告的形式发布。 科伦博泰生物-B(06990)发布公告，近日，本公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物 (ADC)芦康沙妥珠单抗(sac-TMT，亦称SKB264/MK-2870)(佳泰莱)的一项新增适应症上市申请已获中国 国家药品监督管理局(NMPA)批准，用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线 化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子受体2阴性(HER2-)(免疫组织化学 (IHC)0、IHC1+或IHC2+/原位杂交(ISH)-)乳腺癌(BC)成人患者。此次获批的至少经一线化疗治疗 HR+/HER2-BC是芦康沙妥珠单抗(sac-TMT)在中国上市的 ...

本次获批基于OptiTROP-Breast023期临床研究的积极结果，该研究已在2025年欧洲肿瘤内科学会 (ESMO)大会入选最新突破性摘要(LBA)并以口头报告的形式发布。 OptiTROP-Breast02研究评估芦康沙妥珠单抗(sac-TMT)单药对比研究者选择化疗用于治疗不可切除或转 移性的HR+/HER2-BC患者的有效性和安全性。本项3期研究入组患者中，95.7%的患者入组时存在内脏 转移，75.9%的患者存在肝转移;52.9%的患者入组时HER2表达为0(IHC0)，47.1%的患者入组时HER2为 低表达(IHC1+或IHC2+/ISH-);所有患者既往接受过CDK4/6抑制剂和紫杉烷类药物治疗。在晚期或转移 性阶段，56.6%的患者既往接受过≥2线化疗方案治疗。结果显示，芦康沙妥珠单抗(sac-TMT)组盲态独 立评审委员会(BIRC)评估的无进展生存期(PFS)相较于化疗组显示出具有显著统计学意义和临床意义的 改善(8.3个月vs.4.1个月;风险比(HR)，0.35;95%置信区间(CI)：0.26-0.48;p<0.0001);在预先设定的各亚组 中均观察到一致的PFS获益，包括HE ...

Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, with a year-on-year increase of over 60%, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 1 - 2025 marked a milestone year for the company as product revenue surpassed RMB 10 billion, reflecting the successful implementation of its "dual-driven and global innovation" strategy [2] - The company has strengthened its leading position in the oncology treatment sector, expanding its oncology product portfolio to 13 products, with core products like Darbeshou (Sintilimab injection) showing steady growth [2] - The company has successfully ventured into the chronic disease commercialization field, leveraging unmet needs and strong product competitiveness to drive growth, with key products like Xin'ermei (Masitide injection) and Xinbile (Torecilizumab injection) becoming significant revenue contributors [2] Group 2 - The company's global innovation strategy continues to make breakthroughs, focusing on next-generation immunotherapy (IO) and antibody-drug conjugates (ADC) in oncology, as well as innovations in metabolism, cardiovascular, autoimmune, and ophthalmology fields [3] - The company aims to become an internationally leading biopharmaceutical company, supported by its ongoing clinical development and strategic advantages in flexible layout and efficient execution [3]

消息面上，复宏汉霖宣布，收到国家药监局关于同意注射用HLX43联合HLX07及斯鲁利单抗注射液用 于晚期实体瘤治疗开展临床试验的批准。复宏汉霖计划在条件具备后于中国境内开展该联合治疗方案的 II期临床研究。 复宏汉霖(02696)早盘涨超4%，截至发稿，涨3.48%，报56.5港元，成交额1265.25万港元。 公开资料显示，HLX43为复宏汉霖利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子 与其自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物(ADC)，拟用于治疗晚期/ 转移性实体瘤；HLX07为复宏汉霖自主研发的针对EGFR靶点的创新型生物药，拟用于治疗晚期实体 瘤；斯鲁利单抗注射液为复宏汉霖自主研发的创新型抗PD-1单抗。 ...

Core Viewpoint - The recent announcement by Vaili Zhibo has not garnered significant market attention despite the potential of its core product reaching key R&D milestones, which typically attracts investor interest in the Hong Kong stock market for unprofitable 18A companies [3][4]. Market Reaction - Following the announcement, Vaili Zhibo's stock price rose by 3.15% and 1.44% on January 15 and 16, respectively, but subsequently experienced a "three consecutive declines" trend, influenced by the overall pullback in the Hong Kong medical sector and the upcoming cornerstone lock-up expiration [3][4]. - The Hang Seng Healthcare Index reached a peak of 4326.18 points on January 15 before entering a "four consecutive down" trend, indicating a market correction after a period of gains [4]. Trading Volume and Technical Analysis - Vaili Zhibo experienced a "seven consecutive up" trend from December 30 to January 8, coinciding with the company's participation in the JPM conference, but this rally lacked substantial trading volume support, indicating a potential "false breakout" in technical terms [6][8]. - The daily trading volume peaked at 224.58 million shares at the start of the rally but subsequently declined, suggesting a lack of market support and leading to a downward price trend [6]. Cornerstone Lock-up Expiration - Vaili Zhibo's cornerstone investors, who collectively subscribed for $69 million (approximately 542 million HKD) during the IPO, will face a lock-up expiration on January 25, 2025, which could lead to profit-taking and market pressure [8][10]. - As of January 21, the stock price was 51.25 HKD, indicating that cornerstone investors have an approximate 50% unrealized gain, providing them with a favorable exit opportunity [8]. Future Market Dynamics - The upcoming inclusion of Vaili Zhibo in the Hong Kong Stock Connect program in March 2025, with an average market capitalization of 9.462 billion HKD, positions it as a potential target for new capital inflows [10][12]. - The behavior of cornerstone investors during the lock-up expiration will serve as a critical indicator for market sentiment and could influence the stock's performance in the context of new capital entering the market [10][14]. Company Fundamentals - Vaili Zhibo's innovative strategy focuses on T cell connectors, tumor immunology 2.0, and antibody-drug conjugates, with its core product LBL-024 being a significant asset in its pipeline [13][14]. - LBL-024 has received fast track designation from the FDA for treating neuroendocrine cancer, highlighting its potential and the recognition from regulatory bodies [13].